iAward
Sanofi iAwards initiative is a multi-institutional partnership program designed to support collaborations with academic investigators to accelerate innovative early stage, disease-relevant research towards the clinic. With this program, Sanofi aims to fund cutting-edge translational research that can contribute to our early-stage pipeline and ultimately benefit patients.
Eligibility, Guidelines and General Terms
Eligibility
iAwards is open to:
- Asia: Academics and university-affiliated hospitals (single-party submissions only; fee-for-service models are acceptable). No third party collaborators.
- Europe and North America: Academics and medical centers (single-party submissions only; fee-for-service models are acceptable). No third party collaborators.
Pre-Proposal Submission Guidelines
- Coordinate with your Technology Transfer Office (TTO), Office of Sponsored Programs, Office of Corporate Partnership or business office that handles corporate sponsored research to ensure alignment with the program scope and compliance with application criteria (see rules page for details).
- Pre-proposal submissions should be made by your TTO or business office. Pre-proposals must be non-confidential and clearly outline objectives and a 12-month work plan within the specified budget.
-
Formatting requirements:
- Use the official templates provided in the submission form.
- Text must be in Calibri, size 11, single-spaced.
- Save as a Word (.docx) document only.
- Adhere to all length restrictions specified in the template.
General Terms
-
Applicants must:
- Hold the necessary permission and/or license for all technologies used in the proposed work.
- Own the rights to share results with Sanofi for Sanofi's permitted use.
- Grant Sanofi the right to an exclusive option to arising IP.
- Publications: A key outcome of the program is to publish findings resulting from the collaboration following customary authorship guidelines. Sanofi requires limited review periods prior to submission or disclosure to protect any patentable information in a proposed publication. If a publication includes Sanofi confidential information or content requiring copyright or patent protection, it must be revised to remove sensitive material and/or allowed time for appropriate copyright registration or patent filing.